EUVIMEDEUVIMED entdecken
Crossref

How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?

Nakaya A, Fujita S, Satake A, Nakanishiq T, Azuma Y, Tsubokura Y, Konishi A, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S

Journal of Hematology and Blood Disorders · 2018

DOI: 10.15744/2455-7641.4.103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hematology and Blood Disorders, 2018. Verfasst von Nakaya A und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

A, N., S, F., A, S., T, N., Y, A., Y, T., A, K., M, H., H, Y., K, I., T, I., & S, N. (2018). How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?. Journal of Hematology and Blood Disorders. https://doi.org/10.15744/2455-7641.4.103

Vancouver

A N, S F, A S, T N, Y A, Y T, et al. How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?. Journal of Hematology and Blood Disorders. 2018. doi:10.15744/2455-7641.4.103

BibTeX
@article{A2018,
  author = {A, Nakaya and S, Fujita and A, Satake and T, Nakanishiq and Y, Azuma and Y, Tsubokura and A, Konishi and M, Hotta and H, Yoshimura and K, Ishii and T, Ito and S, Nomura},
  title = {How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?},
  journal = {Journal of Hematology and Blood Disorders},
  year = {2018},
  doi = {10.15744/2455-7641.4.103}
}
Kostenlos starten →